Pharma, Inc. , a specialty pharmaceutical firm, today announced extra data from the Company’s Phase 3 study of APF530 for preventing chemotherapy-induced nausea and vomiting . The Company presented the study outcomes today at a poster demonstration during the Multinational Association of Supportive Care in Cancers and the International Society of Oral Oncology International Symposium in NY. As reported previously, the Phase 3 research showed APF530 was comparable to palonosetron in stopping both acute – and delayed-starting point CINV in patients getting either moderately emetogenic chemotherapy or highly emetogenic chemotherapy .Despite increased competition from emerging agents, surveyed pulmonologists and PCPs both display a strong inclination to favor Advair over additional drugs in the arriving years. Additionally, among the three agents in development within the novel LABA/long-performing muscarinic antagonist drug course, surveyed pulmonologists and PCPs view Boehringer Ingelheim’s olodaterol/tiotropium combination to be the most promising. Related StoriesNucala authorized for treatment of asthma patientsSecondhand smoke cigarettes exposure doubles risk of hospitalization for children with asthmaResearchers find protein that plays crucial part in development of allergic airway swelling By the finish of 2013, surveyed pulmonologists expect to prescribe each emerging LABA/ICS combination therapy to between 7 % and ten % of their sufferers, while surveyed PCPs indicate they will prescribe each emerging LABA/ICS combination therapy to between 3 % and 6 % of their patients, said Decision Resources Therapeutic Region Director Melissa Stolper.